Bangladesh Technical Education Board

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Fraser Institute News Release: Size of government on the rise across Canada

Retrieved on: 
Tuesday, March 26, 2024
Bangladesh Technical Education Board, Fraser Institute, Government, Size, Public policy, Research, Policy, Private sector, Crowding, GDP

“The size of government increased in eight of ten provinces and the country as a whole over the last decade-and-a-half,” said Alex Whalen, associate director at the Fraser Institute and co-author of The Size of Government in Canada in 2022 .

Key Points: 
  • “The size of government increased in eight of ten provinces and the country as a whole over the last decade-and-a-half,” said Alex Whalen, associate director at the Fraser Institute and co-author of The Size of Government in Canada in 2022 .
  • The study measures federal, provincial, and local government spending in each province as a share of the economy (GDP) from 2007 to 2022, the most recent year of comparable data.
  • It finds that government size grew in every province except Prince Edward Island and Saskatchewan during that period.
  • Previous research has shown that the size of government (as a share of the economy) to maximize economic growth and social progress is between 26 and 30 per cent of the economy (GDP).

U.S. Congressman Josh Gottheimer Champions Rare Disease Research With Sponsorship of Legislative Bill - H.Res.1039 - Advocating for Increased Funding for Charcot-Marie-Tooth Disease (CMT)

Retrieved on: 
Tuesday, April 9, 2024
Dental, Public Policy, Government, Healthcare Reform, Philanthropy, Biotechnology, Other Health, Health, General Health, Foundation, Stroke, Brain, NJ-5, Gene, Charcot–Marie–Tooth disease, Disease, Sympathetic nervous system, DSM-IV codes, Research, Hope, Quality of life, Hunting, Tax, Child, Spinal cord, Rare Disease Caucus, Legislation, Disability, ID, Bangladesh Technical Education Board, Hearing, CMT, Pharmaceutical industry

The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.

Key Points: 
  • The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.
  • “By collaborating with experts and advocates, we can give everyone struggling with Charcot-Marie-Tooth Disease hope.
  • Zaken's dedication reflects the grassroots efforts of young individuals committed to making a difference in the fight against rare diseases.
  • Regrettably, despite its profound impact, federal funding for CMT research witnessed a decrease in 2022 compared to 2021.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test

Retrieved on: 
Tuesday, April 9, 2024
Medical imaging, ACME, Halo, Human services, SARS-CoV-2, NIH, Acceleration, Clinical trial, National Institutes of Health, POC, BBC, Omicron, Biological engineering, Bangladesh Technical Education Board, Federal, Health department, PBM, Princeton University

The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.

Key Points: 
  • The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
  • "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense.
  • "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled."
  • As always, we remain committed to providing our customers with the best possible solution for at-home testing," added Cox.

Guidehouse Honored with Don Strong Community Partner Award for 2024 by George Washington University Milken Institute School of Public Health

Retrieved on: 
Tuesday, April 9, 2024
Employment, Organization, Public health, Veterans' affairs, Partnership, George Washington University, Public, Knowledge, Food and Drug Administration, University, Human services, Doctor of Philosophy, MD, Student, Bangladesh Technical Education Board, National Institutes of Health, Veritas Capital, Public sector, Medicare, Milken Institute, SPH, Consultant, MHA, Food

WASHINGTON, April 9, 2024 /PRNewswire/ -- Guidehouse , a leading global provider of strategy and managed services to commercial and public sector clients, is proud to announce it has been chosen as the recipient of the Don Strong Community Partner Award for 2024 by the George Washington University Milken Institute School of Public Health (SPH).

Key Points: 
  • WASHINGTON, April 9, 2024 /PRNewswire/ -- Guidehouse , a leading global provider of strategy and managed services to commercial and public sector clients, is proud to announce it has been chosen as the recipient of the Don Strong Community Partner Award for 2024 by the George Washington University Milken Institute School of Public Health (SPH).
  • The Don Strong Community Partner Award is presented to organizations that demonstrate exceptional dedication to advancing public health initiatives and promoting the well-being of communities worldwide.
  • Guidehouse received this prestigious recognition in support of its partnership with the Milken Institute SPH, and steadfast support of the school's mission to educate and train future leaders in public health.
  • Guidehouse was celebrated at the Community Partner Appreciation Event on April 4 at the Milken Institute SPH.

Statement by the Prime Minister on the passing of the Honourable Iona Campagnolo

Retrieved on: 
Saturday, April 6, 2024
Cabinet, International Centre, Today, Human rights, Politics, University, Fitness, Parliament, Woman, Democracy, Iona Campagnolo, Liberal Party, Optimism, Bangladesh Technical Education Board, Lieutenant, Human

OTTAWA, ON, April 5, 2024 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement on the passing of the Honourable Iona Campagnolo:

Key Points: 
  • OTTAWA, ON, April 5, 2024 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement on the passing of the Honourable Iona Campagnolo:
    "Today, I join Canadians in mourning the passing of Iona Campagnolo, a respected politician, former Cabinet minister, and former Lieutenant Governor of British Columbia.
  • She served under my father, Prime Minister Pierre Elliott Trudeau, as Minister of State for Fitness and Amateur Sport, and was a strong voice for women's rights both in Canada and around the world.
  • She was also the first woman to serve as President of the Liberal Party of Canada.
  • "For her decades of tireless service, Mrs. Campagnolo received numerous awards and accolades, including honorary degrees, Indigenous honours, and the Order of British Columbia.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.